The effect of TLR9 signaling on BCR-dependent activation of B cells. We assessed the effect of CpG on several antigen-driven BCR signaling functions in mouse splenic B cells purified by negative selection and treated with soluble polyclonal F(ab ʹ ) 2 antibody specific for immunoglobulin M (anti-IgM), CpG or anti-IgM plus CpG. The effects assessed included the following: phosphorylation of kinases in the BCR signaling pathway ( Fig.  1a-d and Supplementary Fig. 1a -c); Ca 2+ responses ( Fig. 1e and Supplementary Fig. 1d ); the expression of cytokine-encoding mRNA at 3 h after stimulation ( Fig. 1f ) and of cytokines (as protein)
K ey checkpoints in T cell-dependent antibody responses in vivo are dependent on antigen-specific B cell-T cell interactions. The initiation of T cell-dependent antibody responses occurs in secondary lymphoid organs and is dependent on the stable interaction of antigen-primed helper T cells with activated antigen-specific B cells through complexes of peptide and major histocompatibility complex (MHC) class II presented on the B cell surface [1] [2] [3] [4] . Depending in part on the quality of the B cell-helper T cell interaction, B cells either enter germinal centers (GCs) or differentiate into short-lived plasma cells (PCs) and GC-independent memory B cells 2 . Within GCs, the competitive process of affinity selection occurs on the basis of the ability of B cell receptors (BCRs) to capture, process and present antigen to follicular helper T cells (T FH cells). The B cells' successful presentation of antigen to T FH cells ultimately results in the differentiation of GC B cells into long-lived memory B cells and PCs.
B cells also express germline-encoded Toll-like receptors (TLRs) that respond to microbial products that have pathogen-associated molecular patterns [5] [6] [7] . The dual expression of the BCR and TLRs allows B cells to modulate the outcome of antigen encounter in the presence of pathogens 5, 6 . Indeed, TLR9 signaling has been shown to enhance the response of B cells to antigens coupled to the TLR9 agonist CpG, in terms of proliferation and differentiation into antibody-secreting cells both in vitro and in vivo. In addition to signaling for B cell activation, the BCR functions to transport bound antigen to specialized intracellular compartments in which the antigen is degraded and the resulting peptides are bound to MHC class II molecules that are presented on the cell surface for recognition by antigen-specific helper T cells 8 . At present, whether TLR signaling influences the processing and presentation of antigen by the BCR remains unknown.
Although TLR signaling has the potential to amplify humoral responses to antigen 9,10 , B cell-intrinsic TLR signaling does not seem to be required for adjuvant-enhanced T cell-dependent antigen-specific antibody responses in vivo 11 . Although adjuvants can influence several qualities of antibody responses, including kinetics, magnitude and breadth 12 , the ability of adjuvants to augment B cell GC responses, including somatic hypermutation events, has remained unexplored until recently. BCR responses specific to the human immunodeficiency virus envelope protein in nonhuman primates responding to immunization with envelope protein formulated with eight different adjuvants, including ones that target TLR pathways, have now been compared 13 . The adjuvants increased the titer of antibodies specific to envelope protein but, remarkably, did not increase the frequency of somatic hypermutation essential for the development of broadly neutralizing antibodies in this system.
Here we provide evidence that although TLR9 signaling enhanced BCR-induced B cell proliferation and differentiation into antibody-secreting cells, TLR9 signaling reduced the ability of B cells to capture, process and present antigen and to interact with and activate antigen-specific helper T cells in vitro, which was detrimental to the establishment of high-affinity, long-lived antibody responses in vivo. Articles NaTuRe ImmuNoLoGy at 18-24 h (Fig. 1g) ; the proliferative responses of B cells (Fig. 1h ); and concentration of IgM ( Fig. 1i ) and IgG ( Fig. 1j ) in culture supernatants over 7 d. We determined that although treatment with anti-IgM or CpG resulted in different patterns of kinase phosphorylation, the result of treatment with both anti-IgM and CpG was additive and was dependent on the concentration of anti-IgM and, for CpG responses, on TLR9 expression ( Fig. 1a-c and Supplementary Fig. 1a -c). In contrast, B cells underwent Ca 2+ flux only in response to anti-IgM ( Fig. 1e and Supplementary Fig. 1d ), and this response was unaffected by CpG. CpG and anti-IgM acted in synergy to induce high expression of the cytokines IL-2 and TNF at the level of both mRNA and protein, whereas the CpG-induced expression of IL-6 and IL-10 was substantially antagonized by anti-IgM ( Fig. 1f,g ). CpG enhanced, in a TLR9-dependent fashion, the proliferation of B cells treated sub-optimally with anti-IgM ( Fig. 1h and Supplementary Fig. 1e ,f). CpG induced the secretion of IgM by B cells that was weakly antagonized by anti-IgM ( Fig. 1i ), whereas anti-IgM enhanced the CpG-induced secretion of IgG by B cell populations depleted of IgG + B cells ( Fig. 1j and Supplementary  Fig. 1g ). Together these results demonstrated the ability of CpG to alter the B cell response to BCR crosslinking and the ability of BCR crosslinking to alter the B cell response to CpG. We also measured by qPCR the transcription of genes encoding three factors that influence the PC fate of B cells 14 . CpG alone and CpG plus anti-IgM decreased the expression of Bcl6 (which encodes a key transcriptional repressor of PC differentiation whose expression is critical for the maintenance of B cell GC reactions) ( Fig. 1k ), but such treatment increased the expression of Prdm1 (which encodes BLIMP-1, a transcription factor that promotes PC differentiation) ( Fig. 1l ) and Aicda (which encodes the deaminase AID and is upregulated when B cells differentiate toward PCs) ( Fig. 1m ). Together these results provided evidence that TLR9 signaling had the potential to drive B cells toward PC differentiation and away from GC responses.
Internalization and trafficking of soluble antigen by the BCR. We assessed the ability of the BCRs to internalize soluble antigen, either anti-IgM (internalized by C57BL/6 B cells) or hen egg lysozyme (HEL) (internalized by HEL-specific B cells from MD4 mice, which have transgenic expression of a HEL-specific BCR), in the presence or absence of CpG. CpG did not affect the rate or magnitude of the internalization of antigen by BCRs in either case ( Supplementary  Fig. 2a,b ). We characterized the intracellular vesicles into which anti-IgM was internalized by incubating B cells with anti-IgMcoated electron-dense metal particles and imaging the cells by transmission electron microscopy and tomography. Quantification of three-dimensional reconstructions of the images showed anti-IgM + particles in morphologically similar compartments in CpG-treated cells and untreated cells ( Supplementary Fig. 2c -g).
Once internalized into early endosomes, the BCR traffics antigen to increasingly acidic late endosomes. We measured the fluorescence intensity (FI) of HEL-specific MD4 B cells internalizing soluble HEL conjugated to a pH-sensitive dye, the FI of which increases with decreases in pH. For both CpG-treated B cells and untreated B cells, the FI increased at the same rate for the first 20 min at 37 °C ( Fig. 2a,b and Supplementary Fig. 3a ). In the absence of CpG, the FI of the B cells continued to increase with time. In contrast, the FI of the CpG-treated B cells increased little after 30 min, and the block in trafficking was TLR9 dependent ( Fig. 2a,b) .
We further characterized, by confocal microscopy, the endosomal compartments into which the BCR internalized rhodamine-conjugated HEL in the presence or absence of CpG ( Fig.  2c-e ). Cells were fixed and then were stained with the DNAbinding dye DAPI (to label nuclei) and with antibodies specific for the following: the transferrin receptor CD71, a marker of early endosomes; LAMP1, a marker of late endosomes; or H2M, an MHC class II chaperone present in antigen-processing compartments. Three-dimensional colocalization of HEL with CD71, LAMP1 or H2M was quantified by software for the analysis of Supplementary  Fig. 3b ,c). HEL colocalized with CD71 in early endosomes at 10 min, and treatment with CpG had no significant effect on this colocalization (Fig. 2c ). The colocalization of HEL with either LAMP1 or H2M increased from 10 min ( Supplementary   Fig. 3b ,c) to 60 min, and treatment with CpG significantly diminished the colocalization at 60 min ( Fig. 2d,e ). Together these data indicated that TLR9 signaling compromised the BCR's delivery of antigen into late endosomes and the antigen-processing compartments. 
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TLR9 signaling affects B cell responses to membrane-bound antigen. We assessed the effect of CpG treatment on B cell responses to antigen incorporated into fluid planar lipid bilayers. HEL-specific MD4 B cells were labeled with Fab anti-IgM conjugated to the fluorophore Dylight 649 and were placed on bilayers containing HEL labeled with the fluorescent dye Alexa Fluor 488, and live-cell imaging was carried out by total internal reflection fluorescence microscopy [15] [16] [17] (Fig. 3a and Supplementary Video 1a-c). When pretreated for 20 min with CpG, the B cells spread more robustly over the HELcontaining bilayer, covering larger areas, relative to the spreading of untreated B cells ( Fig. 3a,b ), but they did not form a well-organized central synapse and accumulated less BCR ( Fig. 3c ) and HEL (Fig. 3d ) in the contact area. B cells pretreated for 60 min with CpG acted similarly, but they contracted after 90 s and accumulated less BCR than the untreated B cells did but accumulated amounts of HEL comparable to those accumulated by the untreated B cells (Fig. 3d ), suggestive of an antigen-independent component of BCR accumulation, as described earlier 18 .
We also assessed the BCR-dependent internalization of HEL incorporated into plasma membrane sheets (PMSs) by HEL-specific MD4 B cells. B cells were labeled with Dylight 649-Fab anti-IgM and were placed for 30 min at 37 °C on PMSs labeled with fluorescent dye CM-DiI (used for monitoring cell movement), into which Alexa Fluor 488-HEL was incorporated. Confocal z-stack images were obtained and reconstituted as an x view and a z view ( Fig. 3e ) with software program codes that quantify only the internalized antigen, excluding antigen tethered on the PMS surface ( Fig. 3f ).
In the absence of CpG, B cells internalized HEL from the PMS, but in the presence of CpG, the internalization of HEL was much less, as measured by either the proportion of the HEL in the bilayer that was internalized or the total HEL internalized ( Fig. 3f ). We also determined the degree of colocalization of the BCR and HEL, and of HEL and fragments of the PMS, in three-dimensional reconstructed images of the confocal z-stacks of B cells placed on HELcontaining PMSs for 30 min ( Fig. 3g and Supplementary Video 2a,b). HEL, BCR and fragments of the PMS above the contact area with the PMS surface indicated internalization (Fig. 3g ). In the absence of CpG, B cells were frequently observed in contact areas from which the PMS had been cleared, in contrast to CpG-treated B cells, which were observed in areas covered by the PMS. Videos of threedimensional surface images showed that for both CpG-treated cells and untreated cells, little antigen was retained on the B cell surface. In the xy and xz cross sections of B cells not treated with CpG, the BCR and HEL and PMS fragments to which HEL was bound were evidently inside the cell (Supplementary Video 2a,b) where the BCR and HEL colocalized ( Fig. 3h ), as did HEL and PMS fragments ( Fig. 3i ). However, for CpG-treated B cells, although the BCR and HEL were present intracellularly, very few PMS fragments were evident (Fig. 3g ). The colocalization of HEL and the BCR in CpG-treated B cells was similar to that in untreated cells (Fig. 3h) ; however, the colocalization of HEL and fragments of the PMS was significantly lower in CpG-treated B cells than in untreated cells (Fig. 3i ). The lack of PMS fragments in CpG-treated B cells suggested that antigen taken up by BCRs in the presence of CpG did not involve pulling the antigen and attached PMS into the cell but was probably the result of the internalization of antigen that was not tightly attached to the PMS.
Gene transcription and the expression of B cell surface markers.
RNA-based next-generation sequencing (RNA-seq) analysis was carried out on untreated B cells and B cells treated for 4 h with anti-IgM or CpG alone or together. Venn diagramming ( Fig. 4a ) and principle-component analysis (Fig. 4b ) of the results showed notable separation of the transcription profiles of B cells under the different stimulation conditions. Thus, treatment of B cells with anti-IgM and/or CpG resulted in the activation of distinct transcriptional programs. An Ingenuity Pathway Analysis of the genes expressed differentially in B cells treated with anti-IgM or CpG (alone or together) relative to their expression in unstimulated cells showed that a variety of pathways were affected, including those related to cell proliferation and apoptosis, signal transduction, responses to cytokines and cytoskeleton organization ( Fig. 4c ).
We also quantified by flow cytometry the B cell surface expression of approximately 250 mouse cell-surface proteins using a barcoding strategy 19 and a kit with fluorophore-conjugated antibodies for the screening of cell-surface molecules (Fig. 4d ). The expression of 63 surface proteins changed significantly after treatment relative to their expression on unstimulated cells. We observed synergy (up to 55-fold) between CpG and anti-IgM that induced an increase in 48% of the surface proteins; antagonism of anti-IgM responses by CpG for 9.5% of markers; and antagonism of CpG responses by anti-IgM for 8% of surface proteins. The expression of 30% of the surface proteins decreased in response to CpG and/or anti-IgM. Together these results supported the conclusion that signaling through the BCR alone, TLR9 alone or both together resulted in distinct outcomes.
We further analyzed the effect of CpG and anti-IgM on expression of the early activation marker CD69 and three cell-surface molecules that are critical to B cell antigen presentation and activation of helper T cells: MHC class II and the costimulatory molecules CD86 and CD80 ( Supplementary Fig. 4a-g) . The surface expression of MHC class II increased approximately eight-to tenfold at 24-48 h after B cells were treated with anti-IgM alone; this was antagonized by the addition of CpG, via a TLR9-dependent process ( Supplementary Fig. 4c,f) . However, treatment with CpG alone induced a four-to fivefold increase in the surface expression of MHC class II ( Supplementary Fig. 4c,f) , which indicated that CpG initiated at least two signaling pathways through TLR9: one that antagonized BCR-induced expression of MHC class II, and one that independently enhanced the expression of MHC class II. We also assessed the effect of CpG on the ability of HEL-specific B cells from MD4 mice to process HEL and present complexes of HEL peptide and the MHC class II molecule I-A k (HEL-I-A k ) on the B cell surface; for this, we used a monoclonal antibody (mAb) specific for HEL-I-A k . After 24 h of incubation with HEL, HEL-specific B cells significantly increased their cell-surface abundance of HEL-I-A k by approximately 2.5-fold, and the addition of CpG blocked this increase (Fig. 4e,f) .
Neither treatment with CpG nor treatment with anti-IgM had a large effect on CD80 expression at 24 h ( Supplementary Fig. 4b) ; however, after 48 h, the cell-surface expression of CD80 increased approximately twofold for cells treated with CpG alone, anti-IgM alone or both together, and this showed neither antagonism nor synergy ( Supplementary Fig. 4b ). In contrast, treatment with anti-IgM induced a large increase in the expression of CD86 that was blocked by CpG ( Supplementary Fig. 4a,e ). The regulation of the surface expression of CD69 showed a pattern consistent with a simple additive effect of anti-IgM and CpG ( Supplementary Fig. 4d,g) .
We assessed the effects of several inhibitors of kinases in the BCR and TLR9 signaling pathways on the induced expression of MHC class II and CD86. The most consistent effects of the inhibitors were on BCR-induced changes in the expression of both MHC class II and CD86, although these effects were only partial (Fig. 4g,h) . In contrast, the TLR9-induced changes in the expression of MHC class II and CD86 were unaffected by the inhibitors, which suggested, in both cases, the possibility of redundancy in the signaling pathways.
Together these results provided evidence that signaling through the BCR, TLR9 or both triggered distinct transcriptional programs and had differential effects on the expression of cell-surface markers. Of greatest interest was the antagonistic effect of TLR9 signaling on BCR-induced increases in the abundance of peptide-MHC class II complexes and the expression of CD86.
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CpG blocks B cell-helper T cell interactions in vitro.
We assessed the effect of CpG on the length of time antigen-specific B cells and T cells interacted in vitro in the presence of antigen. We labeled HELspecific T cells from 3A9 mice (which have transgenic expression of a HEL-specific TCR) with the cell-tracking fluorescent dye CMTPX and labeled HEL-specific B cells from MD4 mice with cell-tracking fluorescent dye CMFDA, then incubated those cells in culture with HEL alone, CpG alone or HEL plus CpG, imaging the cells continuously over a period of 24 h at a rate of 1 frame per 10-20 min. HEL induced a significant increase in the duration of colocalization of T cells and B cells, and this was antagonized by CpG (Fig. 5a ). The presence of HEL also resulted in a decrease in both the speed and the length of the tracks of T cells, an effect that was mitigated by CpG (Fig. 5b,c) .
We assessed the effect of TLR9 signaling on the ability of antigen-specific B cells to activate antigen-specific T cells in vitro. In the presence of HEL-specific MD4 B cells and HEL (at a concentration of either 0.5 µ g/ml or 2.0 µ g/ml), HEL-specific 3A9 T cells were induced to increase their expression of the activation and memory marker CD44 ( Fig. 5d and Supplementary Fig. 4h ) and proliferate (Fig. 5e ). The addition of CpG to the cultures (at a concentration of either 2.0 µ M or 0.2 µ M) significantly reduced both CD44 expression and T cell proliferation. In the absence of B cells, T cells did not respond to either HEL or CpG. The ability of CpG to antagonize the activation of HEL-specific T cells by HEL-specific B cells was dependent on the expression of TLR9 by B cells but not on the expression of TLR9 by T cells (Fig. 5f,g) . TLR9-sufficent ('wildtype') or TLR9-deficient 3A9 T cells cultured with wild-type MD4 B cells and HEL proliferated and increased their expression of CD44; this was blocked by the presence of CpG. In contrast, CpG had no effect on the proliferation or CD44 expression of either wild-type 3A9 T cells or TLR9-deficient 3A9 T cells induced by TLR9-deficient MD4 B cells. CpG had no effect on the ability of wild-type CD4 + T cells to increase their expression of CD44 Fig. 5a ) on day 14 after intraperitoneal immunization with NP-CGG (100 µ g per mouse) adsorbed onto alum (100 µ l per mouse) and CpG (65 µ g per mouse) (gating strategy, Supplementary Fig. 5c ) Articles NaTuRe ImmuNoLoGy ( Fig. 5h ) or proliferate ( Fig. 5i ) in response to stimulation with plate-bound anti-CD3 and anti-CD28.
Fig. 7 | B cell-intrinsic expression of MyD88 affects the outcome of T cell dependent antibody response in vivo. a, Flow cytometry of splenocytes from chimeric mice with MyD88-deficient B cells (µ MT-MyD88-KO) or wild-type B cells (µ MT-WT) (above plots) (Supplementary
. Numbers adjacent to outlined areas indicate percent GC B cells (CD95 + GL-7 + ) among B cells (top row) or NP-specific cells among GC B cells (bottom row). b-d, Total GC B cells (b), frequency of NP-specific GC B cells among all GC B cells (c) and total NP-specific GC B cells (d) from chimeras as in a (key). e, Flow cytometry of cells from chimeras as in a (above plots). Numbers adjacent to outlined areas indicate percent IgG + IgD -B cells among B cells (top row) or NP-specific cells among those cells (bottom row). f-h, Total IgG
We also assessed the effect of CpG on the ability of B cells to respond to and capture HEL from cell surfaces and to process and present it to HEL-specific 3A9 T cells using NIH3T3 mouse fibroblasts stably expressing a chimeric membrane protein of HEL and the monomorphic co-receptor CD4 via a retroviral vector (NIH3T3-HEL cells) or transduced with a mock vector (NIH3T3-mock cells) ( Fig. 6a,b ). HEL-specific MD4 mouse B cells (but not nonspecific wild-type B cells) captured HEL, as detected by flow cytometry with a HEL-specific mAb (Fig. 6c ), and increased their expression of CD86, MHC class II and CD69 (Fig. 6d ). For both CD86 and MHC class II, the presence of CpG blocked this increase, but it had a synergistic effect on the increase in CD69 expression ( Fig. 6d ). Co-culture of HEL-specific MD4 B cells and 3A9 T cells in the presence of NIH3T3-HEL cells resulted in the activation of T cells to proliferate ( Fig. 6e ) and increase their expression of CD44 (Fig. 6f,g) , but such co-culture in the presence of NIH3T3-mock cells did not, and both of those effects were diminished in the presence of CpG.
Together these results demonstrated that in the presence of CpG, antigen-specific B cells were unable to present soluble antigen or antigen captured from cell surfaces and activate antigen-specific helper T cells.
The effect of CpG on B cell responses in vivo.
To investigate the effect of CpG on B cell responses in vivo, we generated chimeric mice in which the B cells were either wild-type or deficient in the TLR9 adaptor MyD88 and all other hematopoietic cells were wildtype ( Supplementary Fig. 5a ). Reconstitution in the two chimeras was similar ( Supplementary Fig. 5b ). MyD88 deficiency in B cells is not predicted to affect the intrinsic ability of B cells to participate in T cell-dependent antibody responses, as robust T cell-dependent antibody responses are elicited by immunization of MyD88deficient mice in vivo 11 . We immunized the chimeric mice with alum-adsorbed nitrophenyl-chicken γ -globulin (NP-CGG) plus CpG, harvested the spleens on day 14 after immunization and analyzed the cells by flow cytometry according to the appropriate gating strategy ( Supplementary Fig. 5c ). Although the spleen of chimeras with wild-type cells had a larger total number of GC B cells than that in the spleen of chimeras with MyD88-deficient cells (Fig. 7a,b) , the frequency and total number of GC B cells that were NP specific was significantly higher in chimeras with MyD88-deficient cells than in chimeras with wild-type cells (Fig. 7c,d) . Similarly, the total number of IgG-class-switched B cells was higher in chimeras with wild-type cells than in chimeras with MyD88-deficient cells (Fig. 7e,f) , but the opposite was true for the frequency and total number of NP-specific B cells (Fig. 7g,h) . The total number of cells of the PC lineage was greater in chimeras with wild-type cells than in chimeras with MyD88-deficient cells (Fig. 7i,j) , but the number of NP-specific antibody-secreting cells was greater in the spleen of chimeras with MyD88-deficient cells than in that of chimeras with wild-type cells (Fig. 7k,l) . We also determined the total number Articles NaTuRe ImmuNoLoGy of T FH cells (CD4 + CXCR5 + PD1 + ) in the spleen of the chimeric mice at 14 d after immunization and found no significant difference between the chimeras in the number of T FH cells, although the chimeras with wild-type cells tended to have more T FH cells ( Supplementary Fig. 5d,e ). However, without tools to determine the frequency of T FH cells that were antigen specific, that observation was difficult to interpret, given the differences observed for total GC B cells versus antigen-specific GC B cells, isotype-switched B cells and PCs (Fig. 7) . Chimeras with wild-type B cells showed higher NP-specific IgM serum responses than those of chimeras with MyD88-deficient B cells (Fig. 7m) . For total NP-specific IgG, although the peak levels at day 30 after immunization were not significantly different in immunized chimeras (Fig. 7n) , the levels of NP-specific IgG dropped faster in chimeras with wild-type B cells than in those with MyD88-deficient B cells. The most notable differences were in the levels and persistence of high-affinity NP-specific IgG (Fig. 7o) , which reached higher peak levels and persisted for weeks longer in chimeras with MyD88-deficient B cells than in those with wild-type B cells (Fig. 7o) . Thus, CpG drove the production of IgM and shortlived antigen-specific IgG responses that did not undergo affinity maturation in vivo.
The effect of CpG on antibody affinity in humans.
A longitudinal study has been done of the antibody response to a candidate malaria vaccine administered with or without CpG to healthy malaria-naive people in the US (trial NCT00320658 at https://www.clinicaltrials. gov/) 20 . The vaccine was composed of recombinant Plasmodium falciparum apical membrane protein 1 (PfAMA1) formulated on the adjuvant aluminum-hydroxide gel and mixed with 564 µ g of CpG 7909. The inclusion of CpG in the vaccine resulted in significantly higher titers of PfAMA1-specific IgG but did not have an effect on the longevity of the responses 20 .
Using serum samples from that trial 20 , we determined the effect of the inclusion of CpG in the vaccine on the affinity of the IgG response. Serum was collected at 70 d after vaccination from ten people who received the vaccine alone and ten who received the vaccine containing CpG, and IgG was purified on protein G columns (Fig. 8) . The chromatographic profiles of IgG from all people were similar, and the IgG antibodies seemed to be very pure (Fig. 8a) . The purified IgG antibodies were analyzed by BIACore with PfAMA1 recombinant protein adsorbed onto CM5 chips. There was no difference between people who received the vaccine alone and those who received the vaccine containing CpG, in terms of apparent affinity (Fig. 8b ,c) or off rate (Fig. 8b,d) . Thus, although the inclusion of CpG resulted in an increase in the levels of antigenspecific antibody 20 , CpG caused no detectable increase on the affinity of these antibodies.
Discussion
It was established over 30 years ago that the processing and presentation of antigen to CD4 + helper T cells by antigen-specific B cells is highly efficient 21 . However, although it was clear that antigenspecific B cells are able to efficiently process and present antigen, the role of antigen processing and presentation by B cells in T celldependent antibody responses was not elucidated until recently. Several studies have now provided evidence that the ability of B cells to process and present antigen to antigen-activated helper T cells and to T FH cells provides critical checkpoints for the entry of B cells into the GC and for the affinity selection of B cells expressing somatically hypermutated immunoglobulin-encoding genes in the GC [1] [2] [3] [4] . The quality of the B cell's presentation of antigen to antigen-activated T cells at the T cell-B cell border in lymphoid organs determines, in part, if a B cell will enter the GC or differentiate along a GC-independent pathway to become short-lived PCs or GC-independent memory B cells 2 . In the GC light zone, selection by T FH cells is dependent on the density of peptide-MHC complexes on the B cell surface, reflective of the B cell's affinity-dependent ability to compete for the capture of antigen from follicular dendritic cells 3 . Thus, the processing and presentation of antigen by B cells controls, to a large extent, the clonal selection of B cells.
Given the central role of the gathering, processing and presentation of antigen by B cells in the generation of high-affinity, long-lived antibody responses, it is likely that this B cell function is regulated to ensure appropriate and timely responses to antigenic challenge, particularly during infection. However, little is known about the role of receptors of the innate immune system that respond to microbial products containing pathogen-associated molecular patterns in regulating these processes. We found that TLR9 signaling promoted B cell proliferation and the differentiation of B cells into antibody secreting cells, as previously shown 7, 22, 23 , and, in addition, that it triggered changes in gene expression, including the downregulation of the gene encoding BCL6, a transcriptional repressor of PC differentiation, and upregulation of the gene encoding BLIMP1, a transcription factor that promotes PC differentiation. However, TLR9 signaling greatly diminished the ability of antigen-specific B cells to gather, process and present antigen and to interact with and activate antigen-specific CD4 + T cells in vitro. In the presence of CpG, antigen-specific B cells also failed to upregulate their expression of important costimulatory ligands for T cells, including CD86. The ability of CpG to diminish the ability of B cells to capture antigen from membranes and cell surfaces, as shown here, is particularly relevant to the regulation of B cell responses in vivo, where the B cells in lymphoid organs access most antigens on the surface of follicular dendritic cells 24 .
Such findings have implications for the outcome of T cell-dependent antibody responses in vivo. Our data suggest that if B cells encounter TLR9 ligands during an infection, the B cells would have diminished ability to gather, process and present antigen to antigenactivated helper T cells at the T cell-B cell border of lymphoid organs. As a consequence, B cells would be directed to GC-independent pathways and would yield 'affinity-unselected' PCs and GC-independent memory B cells. It might be advantageous to rapidly produce antibodies with a wide range of affinities in response to activation of TLR9 during an acute infection and to leave an unselected broad B cell repertoire for future antigen challenge 2 . Such a mechanism might underlie the observation that, in a nonhuman primate model, although adjuvants that stimulate receptors of the innate immune system, including TLRs, were effective in enhancing the magnitude of antibody responses to protein immunogens, remarkably, these were not able to increase somatic hypermutation 13 .
We have presented evidence both in mice and in humans consistent with that model. We compared the responses of chimeric mice containing wild-type B cells with the responses of chimeric mice containing MyD88-deficient B cells after immunization with an alum-adsorbed protein antigen (NP-CGG) given together with CpG. The ability of B cells to respond to CpG resulted in short-lived low-affinity IgG responses and reduced numbers of antigen-specific GC B cells. We provided evidence that in humans, the inclusion of CpG in a recombinant protein vaccine formulated on alum resulted in increased levels of antigen-specific antibodies but had no detectable effect on the apparent affinity of the antibodies, relative to the response of people who received the vaccine alone. To our knowledge, the studies presented here and a published study 13 are the only ones to address the effect of TLR ligands as adjuvants on antibody affinity maturation. It will be of interest to determine the generality of these findings for other vaccines and vaccine regimens.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0052-z.
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Methods
Mice. C57BL/6, B10.BR-H2K2H2-T18a/SgSnJArc, B cell-deficient (B6.129S2-Ighm tm1Cgn /J) (µ MT) mice, B6.129S2-Ighmtm1Cgn/J, MyD88-deficient mice and B6 CD45.1 + congenic wild-type mice were purchased from Jackson Laboratory. HEL-specific BCR transgenic mice (MD4) 25 , were purchased from Taconic Farms. TLR9-deficient mice were provided by S. Akira (Osaka University, Osaka, Japan). Mice with transgenic expression of a HEL-specific, MHC class II I-A k -restricted TCR (3A9) 26 , were provided by I. Gery (NEI/NIH, Bethesda, MD, USA). Both MD4 mice and 3A9 mice were kept hemizygous for the transgenic alleles in an MHC class II I-A k or I-A b haplotype by crossing 3A9 or MD4 mice with wild-type mice of the relevant haplotype. TLR9-deficient MD4 and 3A9 mice were generated by crossing the MD4 and 3A9 mice with TLR9-deficient mice for at least three generations. TLR9-deficient mice on the MHC class II I-A k haplotype were generated as the F2 generation of a cross between TLR9-deficient mice (I-A b ) and B10.BR-H2K2H2-T18a/SgSnJArc (I-A k ) mice. These TLR9-deficient I-A k mice were further crossed (at least four generations) with TLR9-deficient MD4 or 3A9 mice to obtain TLR9-deficient MD4 or 3A9 mice in the I-A k haplotype. Mice were bred and maintained in NIH animal facility according to Animal Care and Use Committee Standards.
Antibodies and proteins. Antibodies specific for the following mouse molecules were purchased from BioLegend: CD19 (Clone:6D5) (conjugated to Alexa Fluor 488, Alexa Fluor 700, BV650, PeCy7 or BV421); CD45R/B220 (Clone:RA3-6B2) (conjugated to PE, Alexa Fluor 488, Alexa Fluor 647, Alexa Fluor 700, BV421, BV785, BV605 or BV510); CD80 (Clone:16-10A1) (conjugated to Alexa Fluor 647); CD86 (Clone: GL1) (conjugated to PERCP, PERCP-Cy5.5 or Alexa Fluor 488); IgM (Clone:RMM-1) (conjugated to BV605); CD69 (Clone: H1.2F3) (conjugated to PE or BV605); CD4 (Clone:RM4-5) (conjugated to Alexa Fluor 488 or BV605); CD44 (Clone:IM7) (conjugated to Alexa Fluor 700 or Alexa Fluor 647); MHC class II I-A b (Clone:KH74) (conjugated to Alexa Fluor 488); MHC class II I-A k (Clone: 10-3.6)(conjugated to PE); IgG1 (Clone: RMG1-1)(conjugated to biotin or Alexa Fluor 647) and IgG2a (Clone:RMG2a-62) (conjugated to Alexa Fluor 647), CD138 (Clone:281-2) (conjugated to PE), CD45.2 (Clone:104) (conjugated to BV650 or APC), CD45.1(Clone:A20) (conjugated to Alexa Fluor 700, Alexa Fluor 488 or APC), CD3e (Clone: 145-2C11), CD28 (Clone:37.51) and streptavidin (PE conjugated). Isotype-matched control antibodies to mouse IgG1 (Clone:MG1-45) and IgG2a (Clone:MG2a-53) were purchased from BioLegend. Antibodies specific for the following were purchased from BD Biosciences: p-Btk (p-Y223) (Clone:N35-86) (conjugated to PE); pMAPK/p38 (pT180/pY182) (Clone:36/ p38) (conjugated to Alexa Fluor 647); p-Syk (pY352) (Clone: 17 A/P-ZAP70) (conjugated to Alexa Fluor 488); pAkt (pS473) (Clone:M89-61) (conjugated to Alexa Fluor 647); H2-M (Clone: 2E5A) (unconjugated) and CD71 (unconjugated) (Clone C2F2) and, anti-mouse IgD (Clone:11-26 c.2a) conjugated to BV786. Polyclonal F(ab′ ) 2 anti-mouse IgG (conjugated to Alexa Fluor 647 or Alexa Fluor 488) and polyclonal F(ab′ ) 2 anti-mouse IgM (unconjugated and conjugated to Alexa Fluor 647) were purchased from Jackson ImmunoResearch. Antibodies specific for mouse CD95 (Clone:15A7) (conjugated to Percp e710) and mouse IgM Clone:eb121-15F9) (conjugated to e450) were purchased from ThermoFisher. Antibodies specific for LAMP-1 (Clone:1D4B) were purchased from Santa Cruz Biotechnologies. PE-conjugated NP was purchased from Biosearch Technologies. The mouse mAb (OX68) specific for the third and fourth domains of rat CD4, as described 27 , was provided by N. Barclay (University of Oxford, Oxford UK). The hybridoma secreting mouse mAb (AW3.18) specific for the HEL peptide (residues 4862)-MHC class II I-A k complex 28 , was provided by P. Roche (NCI/NIH, Bethesda, MD, USA) and purified antibody was produced by L. Lantz (NIAID/NIH, Rockville, MD,USA). The mouse mAb (F10.6) specific for HEL 29 , was provided by J. Charles-Guery and D. Hudrisier (University of Toulouse, Toulouse, France). Fluorescent labeling of the unconjugated antibodies was done using a LYNX kit purchased from Bio-Rad.
Flow cytometry. Flow cytometry was performed on a BD LSRII flow cytometer and data were analyzed in Flowjo software (Tree Star). During analysis, dead cells were excluded by staining with LIVE/DEAD fixable dead cell stain kits (ThermoFisher).
Cells. B cells and naive CD4 + T cells were isolated from mouse spleen using mouse B cell and naive T cell isolation kits (Miltenyi Biotech) according to previously published optimized protocols 30, 31 . NIH3T3 mouse fibroblast cell line (ATCC CRL-1658) was provided by O. Voss. Phoenix Eco retroviral packaging cell line (ATCC CRL-3214) was purchased from American Type Culture Collection (ATCC). All cells were maintained in RPMI 1640 media supplemented with 50 µ M 2-mercaptoethanol, 50 U/ml penicillin, 50 µ M streptomycin, 2 mM lglutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES unless specified otherwise. The pathway inhibitors SP600125, PD98059, Wortmannin, Rapamycin, SB202190 were purchased from Invivogen. MHY1485 and Akt Inhibitor IV (Akt IV) were purchased from Sigma-Aldrich.
B cell-T cell co-culture. B cells were isolated from the spleens of MD4 mice on the MHC class II I-A k haplotype. Naive T cells were isolated from the spleen and lymph nodes of 3A9 mice. Both cells were labeled with Cell Proliferation Dye eFluor 450 (ThermoFisher), mixed at 1:1 ratio (7.5 × 10 4 each) in complete medium and incubated in 96-well plates at 37 °C in the presence of HEL (1 µ g/ml) and/or CpG (1 µ M). Stimulation by membrane-bound antigens was carried out by plating NIH3T3 cells, transfected to stably express HEL or mock transfected, in 96-well plates, 5 × 10 4 cells per well, 1 d before adding the B cell-T cell mixture.
Visualization of real time interactions between B cells and T cells was carried out by labeling B cells and T cells with CellTracker Green CMFDA and CellTracker
Red CMTPX (ThermoFisher), respectively. Labeled cells were plated into 48-well plates at 1:1 ratio (1 × 10 5 each) and stimulated as indicated above. Interactions between cells were recorded as 10-to 20-min time-lapse photos by IncuCyte ZOOM system (Essen Bioscience) for 24 h. Image analysis was performed using Imaris Software.
Human study population and vaccination procedures. Serum was obtained 70 d after immunization from malaria-naive adults enrolled in a phase 1 clinical trial of the blood-stage malaria vaccine candidate AMA1-C1 (80 µ g), formulated on Alhydrogel and mixed with CpG 7909 (564 µ g) 32 (trial NCT00320658 at https://www.clinicaltrials.gov) as detailed elsewhere 20 . The trial was conducted under Investigational New Drug Applications reviewed by the US Food and Drug Administration and was reviewed and approved by the National Institute of Allergy and Infectious Diseases Review Board and by the University of Rochester Institutional Review Board and funding agency. Written informed consent was obtained from all participants. Serum samples from 20 subjects were randomly selected for analysis; half of the subjects had been vaccinated with CpG7909containing vaccine and half had been vaccinated with the vaccine alone.
Generation of stable cell lines expressing HEL chimeric protein. NIH3T3 cells
stably expressing HEL on their surface were generated by transfection with a construct encoding a protein chimera containing on its amino terminus the entire HEL protein (NCBI protein database accession code AAA48943.1), followed by a serine-tyrosine linker sequence and then by the third and fourth transmembrane and intracellular domains of rat CD4 (residues 206-457) (NCBI protein database accession code P05540.1). A codon optimized final construct was generated by Geneart Gene Synthesis (ThermoFisher) and was then subcloned into a pFB-Hygro retroviral vector 33 . Transduction of NIH3T3 cells using the Phoenix-Eco system and selection of the stably transfected cells were done as previously described 34 .
Bone marrow chimeras and immunizatios. To generate mice with B cell lineage-specific TLR9-deficiency, lethally irradiated 7-to 8-week-old C57BL/6 mice (CD45.1 + haplotype) were reconstituted with 1 × 10 7 bone marrow cells, of which 90% were from µ MT mice and 10% were from either MyD88-deficient mice or wild-type mice. Mice were allowed to reconstitute for at least 8 weeks before intraperitoneal immunization with both 100 µ g NP 15 -CGG (Biosearch Technologies) adsorbed into 100 µ l Alum (ThermoFisher) in PBS and 65 µ g CpG B (ODN 1826) (Invivogen) in PBS.
Signaling pathway analysis. B cells isolated from mouse spleen were cultured in 96-well plates at 37 °C with the appropriate stimulus. At each time point, cells were fixed with 4% PFA containing HBSS buffer for 10 min at 37 °C, followed by permeabilization on ice using pre-chilled Perm Buffer III (BD Biosciences) for 30 min. Cells cultured with different stimuli were barcoded by staining with antibodies to B220 (identified above) conjugated to different fluorochromes. Following barcoding as described 19 , samples from the same time point, each having unique B220 staining patterns, were pooled into one well for intracellular staining using phosphorylated kinase-specific antibodies (identified above). For flow cytometry, each sample was gated based on the barcodes. For each phosphorylated kinase-specific antibody, the net mean fluorescence intensity (MFI) was calculated by subtraction of the MFI of the fluorescence-minus-one (FMO) control from the MFI of the actual samples. The change in the phosphorylation content (fold value) was determined as the ratio of the net MFI of a stimulated condition to the net MFI of the unstimulated sample at the same time point. Changes in calcium influx into the cell as a response to different stimulation conditions were analyzed using Fluo-4 and Fura red dyes (ThermoFisher) as explained 20 .
Characterization of BCR-mediated antigen internalization.
To quantify internalization of antigen from solution, B cells isolated from mice with transgenic expression of a HEL-specific BCR (MD4) were incubated with saturating amounts (4 µ g/ml) of soluble HEL (Sigma-Aldrich) on ice for 30 min. Unbound antigen was removed by repeated washes at 4 °C. Cells were cultured in complete medium with or without CpG at 37 °C, and aliquots were taken with time and transferred to ice cold FACS buffer (HBSS supplemented with 5% FCS, 10 mM HEPES and 10 mM sodium azide). Cells were stained with Alexa Fluor 647-conjugated antibody specific for mouse IgM and analyzed by flow cytometry. Downmodulation of the surface BCR was measured using the following formula: % receptor downmodulation = 100 × [net MFI (t x )/net MFI (t 0 )].
Alternatively, B cells isolated C57BL/6 mouse spleens were incubated on ice with Alexa Fluor 647-conjugated anti-IgM (identified above) for 30 min, then were washed and cultured at 37 °C for increasing lengths of time. At each time Articles NaTuRe ImmuNoLoGy sequencing reads were first prepped by removal any illumina adaptor sequences using Cutadapt v1.12 44 and then were trimmed and filtered for quality, q = 18, and length, min length 35 bp using FastX Tool Kit v0.0.13 (Hannon Lab, Cold Spring Harbor Laboratory). Trimmed reads for each replicates were then mapped to Mus musculus mm10 genome using Tophat2 v2.1.1 45 set to report only matched pairs. Final transcripts based on the combined replicates, and then differentials for each comparison were generated with the Cufflinks suite 45 using pooled normalization for each experimental condition. Changes in the transcriptional regulation of various pathways were analyzed using Ingenuity Pathway Analysis software (Qiagen).
Purification and surface plasmon resonance (BIAcore) binding analysis of antibodies to PfAMA1. Total serum IgG antibodies from PfAMA1-immunized subjects were purified by protein G affinity chromatography. In brief, 0.5 ml serum from each individual subject was loaded onto a 5 ml HiTrap Protein G column (GE healthcare) and was subjected to a standard elution with a glycine pH gradient. The eluted IgG proteins were pooled together and dialyzed against 10 mM HEPES (pH 7.5) and 0.15 M NaCl for binding studies.
Surface plasmon resonance measurements were performed using a BIAcore 3000 instrument and were analyzed with BIAevaluation 4.1 software (Biacore AB). To measure the affinity, PfAMA1 protein was immobilized on caboxylated dextran CM5 chips (Biacore AB) to 500-1,500 response units using a primary amine coupling and a flow rate of 10 µ l/min in 10 mM sodium acetate (pH 4.5). The analyte consisted of serial dilutions of IgG antibodies between 16.0 nM and 75 nM in a buffer containing 10 mM HEPES (pH 7.4) and 0.15 M NaCl. The dissociation constants were obtained by kinetic curve fitting using BIAevaluation 4.1 (BIAcore).
Statistical analysis.
The statistical significance of differences between experimental groups was measured using GraphPad Prism software. The methods used for each experiment and the P value ranges were indicated in the relevant figure legends.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability statement. The data that support the findings of the study are available from the corresponding author upon request. RNA-seq data were uploaded to the SRA database under project number PRJNA422889. Corresponding author(s): Susan K. Pierce
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